Page 10 - சுயாதீனமான தகவல்கள் கண்காணிப்பு குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company
teletrader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from teletrader.com Daily Mail and Mail on Sunday newspapers.
Why Tonix Pharmaceuticals Stock Is Crashing Today
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, July 7, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Citius Pharmaceuticals, Inc. ( Citrus or the Company ) (NASDAQ: CTXR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Citius and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On July 1, 2021, Citius issued a press release entitled Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok Phase 3 Trial as Planned. Although the press release framed its contents in positive terms, disclosing, among other things, that following a unblinded data review of safety and efficacy, the independent Data Monitoring Committee (DMC) for the Mino-Lok® Phase 3 Pivotal Superiority Trial has recommended proceeding
Paragon Biosciences Jeff Aronin Supporting Trials for the Treatment of Tourette Syndrome, Stuttering : Science : University Herald
universityherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from universityherald.com Daily Mail and Mail on Sunday newspapers.
the global fight against this disease.”
Investigators and the Independent Data Monitoring Committee observed slightly higher deaths in the treatment arm compared to placebo without causality being established. Results from this trial, including translational data, are planned to be submitted for publication.
Based on these results, the Company will stop exploring avdoralimab in COVID-19. Today’s results do not impact the investigator-sponsored, Phase 2 trial of avdoralimab in bullous pemphigoid, an inflammatory disease, which is currently enrolling patients. More than 100 patients have been treated with avdoralimab in inflammation and oncology clinical trials with no new or unexpected safety signals observed.
About the FORCE clinical trial: